NL-OMON29995
Completed
Phase 2
An open label phase IIa trial to assess efficacy and tolerability of a once a week oral dose of 200 mg R126638 in disto-lateral toenail onychomycosis. - R126638 in toenail onychomycosis
Barrier Therapeutics0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- toenail fungi
- Sponsor
- Barrier Therapeutics
- Enrollment
- 20
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and female subjects of 18 to 70 years old including extremes.
- •2\. Clinical diagnosis of disto\-lateral onychomycosis of the toenails.
- •3\. Diagnosis confirmed by microscopic examination and culture
- •4\. If the subject is of childbearing potential, she must have a negative urine pregnancy test at inclusion and agree to use effective forms of birth control (double barrier method) during the duration of the clinical trial or until the first menses after 60 days following the last dose of study medication, whichever is longer. She must be on a stable regimen, for at least one month, of oral contraceptives, contraceptive implant or depot injection, contraceptive patch, IUD, condom and spermicidal agent or diaphragm and spermicidal agent.
- •5\. Availability of a signed informed consent prior to beginning protocol\-specific procedures, indicating an understanding of the purpose of this trial and a willingness to adhere to the treatment regimen and trial procedures described in this protocol.
- •6\. The subject is in good health and free of any disease or physical condition which, in the investigator\*s opinion, might impair evaluation of onychomycosis of the toenail(s).
Exclusion Criteria
- •1\. More than 50% involvement of the most severely affected toenail.
- •2\. An involvement of the nail matrix.
- •3\. Lateral onychomycosis involving \> 50% of the length of the most severely affected toenail.
- •4\. Extensive hyperkeratosis (\>3mm nail thickness) on the most severely affected toenail.
- •5\. An involvement nail of the little toes only
- •6\. Psoriasis or diabetics.
- •7\. History of significant sensitivity, or significant allergy to azoles or related drugs or any ingredient in the study medication.
- •8\. Severe coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic pancreatitis, or a history indicating adrenal cortex dysfunction or any other serious disease (including cancer and subjects known to be HIV positive).
- •9\. History of heart\-failure, myocardial infarction within the past six months, cardiac arrhythmia, or under treatment for heart disorders.
- •10\. Clinical significant abnormal ECG\-intervals or morphology of the ECG, QT or QTc\>450 ms.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open label phase IIa trial to assess efficacy and tolerability of a once a week oral dose of 200 mg R126638 in disto-lateral toenail onychomycosis. - R126638 in toenail onychomycosisOnychomycosisMedDRA version: 8.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2005-004611-30-NLBarrier Therapeutics nv20
Active, not recruiting
Not Applicable
An open label phase IIa trial to assess efficacy and tolerability of a once a week oral dose of 200 mg R126638 in disto-lateral toenail onychomycosis. - R126638 in toenail onychomycosisOnychomycosisEUCTR2005-004611-30-BEBarrier Therapeutics nv20
Active, not recruiting
Not Applicable
Phase II open label trial to assess the efficacy and the impact on QTcF of continuous oral BIBW 2992 at a daily dose of 50 mg in patients with relapsed or refractory solid tumours including patients with brain metastases and those with glioblastoma not amenable to other therapyPatients diagnosed with EGFR/HER2-positive solid tumour cancers with and without brain metastases, and patients with recurrent glioblastoma.MedDRA version: 9.1Level: LLTClassification code 10018336Term: GlioblastomaMedDRA version: 9.1Level: LLTClassification code 10006128Term: Brain metastasesMedDRA version: 9.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2008-006288-36-GBBoehringer Ingelheim Limited60
Active, not recruiting
Not Applicable
An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen -HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen in two cohorts of patientsTwo Cohorts: Cohort A: Triple negative metastatic breast cancer, i.e. HER2-negative, estrogen-receptor-negative and progesterone receptor negativeCohort B:HER2-negative, estrogen-receptor-positive and/or progesterone-receptor positiveMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002018-36-BESCS Boehringer Ingelheim Comm.V60
Active, not recruiting
Not Applicable
An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen -HER2-negative metastatic breast cancer after failure of no more than three chemotherapy regimen in two cohorts of patientsTwo Cohorts: Cohort A: Triple negative metastatic breast cancer, i.e. HER2-negative, estrogen-receptor-negative and progesterone receptor negativeCohort B:HER2-negative, estrogen-receptor-positive and/or progesterone-receptor positiveMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002018-36-DEBoehringer Ingelheim Pharma GmbH & Co. KG60